И. Г. Русаков
City Clinical Hospital · 120 works · 1,958 citations · h-index 5
Top works
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways
- In vivo local fluorescence spectroscopy in PDD of superficial bladder cancer
- BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
- 901 SOMATOSTATIN ANALOG IN THE TREATMENT OF ANDROGEN-INDEPENDENT PROSTATE CANCER BEFORE AND AFTER CHEMOTHERAPY
- Effect of luteinizing hormone-releasing hormone agonists on the testosterone levels and quality of life in patients with locally advanced and generalized prostate cancer
- DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
- DETECTION OF SENTINEL LYMPH NODES IN PROSTATE CANCER PATIENTS
- HORMONAL THERAPY WITH LEUPRORELIN (LUCRIN-DEPOT®) IN PATIENTS WITH PROSTATE CANCER
- Stable castration level of testosterone in androgendeprivation therapy for clear cell renal cell carcinoma
- The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
- [Fluorescent diagnostic methods and superficial cancer of the urinary bladder: current status].
- Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer
- Intermittiruyushchaya gormonal'naya terapiya pri rake predstatel'noy zhelezy s posledovatel'nym naznacheniem lyuteiniziruyushchego gormona-rilizing-gormona i antiandrogenov
- Atezolizumab (Tecentriq) as first-line therapy in patients with metastatic urothelial carcinoma
- Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer
- Buserelin-long PhC in the treatment of disseminated prostate cancer
- The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer
- MP22-18 IDENTIFICATION OF NOVEL GENE EXPRESSION MARKERS FOR BLADDER CANCER DIAGNOSTICS
- The role of sunitinib in the therapy of metastatic renal cell carcinoma